Tuesday, June 22, 2021 5:36:46 AM
Hard to believe they scammed The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services.
Development plan for Glioblastoma drug anticipates being prepared for First-in-Human clinical trial within 18 months. 18 months is around March 2022.
Still a window to develop.
We should direct questions to Michael K. Fish - Independent Director and Chairman of the Audit Committee. Would hope the licensed CPA has some integrity.
Bernie Madoff has got nothing on these guys, lol.
Ready to load those .04's!!!
Recent CUBT News
- Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy • GlobeNewswire Inc. • 04/15/2026 12:08:00 PM
- Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting • GlobeNewswire Inc. • 03/23/2026 11:05:00 PM
- Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- Curative Biotechnology Announces Canadian Patent Allowance • GlobeNewswire Inc. • 01/23/2026 01:45:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 12/22/2025 06:40:01 PM
- Curative Biotechnology, Inc. Announces Letter to Shareholders • GlobeNewswire Inc. • 11/18/2025 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/01/2025 08:07:47 PM
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 05/09/2025 07:00:02 PM
